Why Merck & Co., Inc.’s (MRK) Stock Is Up 5.07%
As of Monday, May 12, Merck & Co., Inc.’s MRK share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Commentary & Analysis
What You Need to Know About Merck & Co., Inc.'s Q2 Earnings
Merck & Co., Inc.'s fiscal Q2 earnings report was released on Thursday, April 24. Let's dive in to see if (MRK) missed or beat analyst's expectations.Omar Beirat
Which Is a Better Investment, Jazz Pharmaceuticals plc or Merck & Co., Inc. Stock?
Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Aneeqa Nadeem
Which Is a Better Investment, Corcept Therapeutics Incorporated or Merck & Co., Inc. Stock?
Learn more about whether Corcept Therapeutics Incorporated or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Intra-Cellular Therapies, Inc. or Merck & Co., Inc. Stock?
Learn more about whether Intra-Cellular Therapies, Inc. or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Aneeqa Nadeem
Financial Summary
| Share Statistics | MRK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $360,083.7 | $452.3 | 99% |
|
| Shares Out (Mil) | 2,470.0 | 42.7 | 98% |
|
| Institutional Ownership | 99.9% | 81.2% | 96% |
|
| Float (Mil) | 2,463.0 | 44.3 | 96% |
|
| Beta | 0.21 | 0.71 | 13% |
|
| Avg Daily Volume (000s) | 9,278 | 357 | 96% |
|
| Price Change (52-week) |
73.5% | 53.8% | 92% |
|
| Growth | MRK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 9.4% | 6.1% | 56% |
|
| Net Income (5yr) | 20.9% | (2.4%) | 75% |
|
| EPS (5yr) | 21.2% | 14.9% | 70 |
|
| Dividends (5yr) | 5.8% | 0.0% | 95% |
|
| Cash Flow (5yr) | 22.7% | (15.1%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 19 | 25 | 22 | |
| Current EPS | $2.089 | $2.657 | $9.291 | |
| Month Ago EPS | $2.211 | $2.745 | $9.551 | |
| # Rev Up | 1 | 8 | 1 | |
| # Rev Down | 0 | 5 | 0 | |
| Three Months Ago EPS | $2.296 | $2.754 | $9.662 | |
| Year/Year Chg | (486.9%) | (63.5%) | 40.8% | |
| Financials | MRK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $66,569 | $416 | 98% |
|
| Net Income (TTM) (Mil) | $3,173 | ($11) | 95% |
|
| EPS (TTM) | $1.280 | ($0.700) | 64% |
|
| Operating Cash Flow (TTM) (Mil) | $19,967 | ($7) | 99% |
|
| Net Cash Flow (TTM) (Mil) | ($1,182) | $5 | 3% |
|
| Long-Term Debt (Q1) (Mil) | $51,086 | $6 | 98% |
|
| Enterprise Value (Q1) (Mil) | $415,762 | $493 | 99% |
|
| Valuation | MRK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.59 | 2.13 | 89% |
|
| P/E | 114.7 | 17.4 | 95% |
|
| Dividend Yield | 2.3% | 0.0% | 78% |
|
| PEG (5yr hist) | 3.5 | 1.1 | 82% |
|
| Ratios | MRK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.9% | 69.4% | 86% |
|
| Net Margin | 4.8% | 3.2% | 47% |
|
| ROA | 2.6% | (22.2%) | 59% |
|
| ROE | 7.0% | (21.0%) | 48% |
|
| Liabilities to Assets | 67.7% | 32.8% | 63% |
|
| F-Score | 4 | 3 | 33% |
|
Passing Stock Screens
As of 10/16/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Dogs of the Dow Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 4.1% |
| +/- S&P 500: | -3.4 |
FACTOR STRATEGY
Dogs of the Dow: Low Priced 5 Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 2.3% |
| +/- S&P 500: | -5.2 |
